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 Chagas disease is caused by infection with the parasite Trypanosoma cruzi, which 
might lead to a chronic disease state and drive to irreversible damage to the heart and/or 
digestive tract tissues. Endemic in 21 countries in the Americas, it is the neglected disease 
with a highest burden in the region. Current estimates point at ~6 million people infected, of 
which ~30% will progress onto the symptomatic tissue disruptive stage. There is no vaccine 
but there are two anti-parasitic drugs available: benznidazole and nifurtimox. However, their 
efficacy is variable at the chronic symptomatic stage and both have frequent adverse effects. 
Since there are no prognosis markers, drugs should be administered to all T. cruzi-infected 
individuals in the indeterminate and early symptomatic stages. Nowadays, there are no tests-
of-cure either, which greatly undermines patients´ follow-up and the search of safer and more 
efficacious drugs. Therefore, the identification and validation of biomarkers of disease 
progression and/or treatment response on which to develop tests of prognosis and/or cure is 
a major research priority. Both parasite- and host-derived markers have been investigated. In 
the present manuscript we present an updated outlook of the latter. 
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Chagas disease is caused by infection with the protozoan parasite Trypanosoma cruzi 
(T. cruzi). It affects ~6 million people around the world, mostly in Latin America (1), and it 
is estimated that approximately ~30% of them will eventually progress to the symptomatic 
life-threatening stages of the disease that entail cardiac and/or digestive tissues disruptions 
(1). This organ involvement, which can lead to the Chagas disease characteristic mega-
syndromes, does not occur immediately but it is rather observed upon several years of 
infection (even 10 to 30 years) (2,3). Unfortunately, at present there is not a way to predict 
this possible progression. Being able to anticipate it would be crucial to tailor the needs of 
patients based on their risk of progression. This would mean a breakthrough in the 
management of the disease considering the limited resources available. Thus, finding 
prognosis markers to assess the risks of progression and predict the early stages of organ 
involvement is one of the main objectives of biomarker research projects in the field. 
On the other hand, despite there are two drugs to treat T. cruzi infection, benznidazole 
(BNZ) and nifurtimox (NFX) (2,3), both have a poor safety profile that forces clinicians to 
discontinue a high percentage of treatments (4–6). Besides, although BNZ and NFX have a 
very good efficacy against the acute stage of the disease, it is at the chronic stage that the 
infection is generally diagnosed and treated. By then drugs´ efficacy is reduced. Limitations 
of currently available drugs unveil the requirement of biomarkers for the early assessment of 
treatment response so that a closer and accurate follow-up of treated patients can be made. 
Availability of such biomarkers would allow the development of tests of cure based on them. 
These tests would also be very useful in the search of safer and more efficient new therapeutic 
options. A major obstacle for the clinical evaluation of new treatments is that the current 
“gold standard” of cure is the negative seroconversion of treated patients, which occurs years 
or decades after treatment (7,8). This time scale is impractical from the viewpoint of the daily 
clinical management of patients, as well as for the interpretation of the outcome of clinical 
trials with new drugs or with new regimens of existing ones. Thus, it is urgent to identify and 
validate biomarkers for the early assessment of therapeutic efficacy too. 
Finding reliable biomarkers of disease progression and/or treatment response would 
mean the greatest leap forward in the history of Chagas disease since its discovery in 1909 
by Dr. Carlos Chagas. For this reason there are numerous research groups devoted to the 
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search of both host-derived and T. cruzi-derived biomarkers (9). With the aim to host 
discussions on the subject and nurture joint investigations appeared the NHEPACHA 
network (10). Since its inception in 2012 it has produced some important advances in the 
field as a result of multidisciplinary and transnational collaboration, like a paradigm shift 
proposal for the treatment of chronically infected people (11), or the elaboration of the first 
Target Product Profile document for a test to early address treatment response (9). Standing 
on these and other works, it is the purpose of this article to review the research on host-
derived biomarkers for Chagas disease providing an updated overview of the advances made, 
and outlining state-of-the-art investigations in the field. 
 
2. Host-derived biochemical markers for the management of Chagas disease. 
Research on biochemical markers gathered attention in the last years due to their 
potentially simple analysis and low cost, which makes them easy to implement in middle- 
and low-income countries (9). In the case of Chagas disease, several biomarkers have been 
proposed for the assessment of cardiac and/or digestive involvement (12) (Figure 1). In 
addition, there are also some examples of biochemical markers proposed for the early 
evaluation of treatment response (13). We summarize all biochemical markers identified so 
far in the context of Chagas disease and their proposed application in Table 1. Unfortunately, 
despite recent advancements, we are yet far from having one single molecule that meets all 
the required expectations. Due to the complexity of the chronic stage of the disease, the 
option of using a battery of biomarkers rather than relying on a single one to assess treatment 
response and/or anticipate pathological progression of the infection appears more likely (9). 
 
2.1. Biochemical markers for the evaluation of treatment response. 
Setting the focus on biomarkers of treatment response, there are two main groups of 
molecules identified up to now: those related to the metabolism of lipids (13,14), and those 
associated to the hypercoagulability state (15,16). 
2.1.1. Markers based on lipid metabolism intermediates. 
A study by Santamaria and co-workers with sera from 37 adult Chagas disease 
patients and 37 healthy subjects showed that apolipoprotein A1 (ApoA1) and certain 
fragments of ApoA1 and fibronectin (FBN) proteins were interesting for the evaluation of 
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treatment response. Higher levels of fragments of ApoA1 and FBN were found in serum 
samples of T. cruzi seropositive patients in comparison to the control group. Contrarily, full-
length Apoa1 levels were lower in T. cruzi infected individuals compared to healthy donors 
(13). Such altered levels of ApoA1, its specific fragments thereof, and a fragment of FBN 
returned to normal in 43% of the studied T. cruzi-infected subjects three years after NFX 
treatment (13). These results have been recently validated in a cohort of 30 T. cruzi 
seropositive children treated with BNZ (14). In the latter study, ApoA1 and FBN fragments 
were absent at the end of BNZ treatment in a significant part of the cohort (66.6% and 53.3% 
of the children respectively for ApoA1 and FBN) (14). Also, correlation between 
seroconversion of the children upon treatment and absence of detection of ApoA1 and FBN 
fragments in serum samples was observed in 100% and 96.6% of the cases, respectively (14). 
 
2.1.2. Hypercoagulability state biomarkers. 
The presence of a hypercoagulability state in T. cruzi-infected patients was described 
a few years ago (15,16), which contrasted with other report by Melo and co-workers (17). 
Notwithstanding, at the clinical level, the presence of a coagulation state condition could be 
hinted upon the description of the occurrence of thromboembolic events in T. cruzi-infected 
patients who did not show any signs of cardiomyopathy (18). In 2016, some of us published 
the results of a clinical study with plasma samples from 56 chronically T. cruzi-infected adult 
patients and reported that a high percentage of them had statistically significant altered levels 
of the hypercoagulability markers prothrombin fragment 1+2 (F1+2) and endogenous 
thrombin potential (ETP) (19). These two markers, which had not been looked upon by Melo 
et al., were abnormally expressed in respectively 77% and 50% of the patients (19). 
Moreover, after BNZ treatment, both markers returned to and remained at their normal levels 
in respectively 76% and 96% of the patients by 36 months upon end of treatment (19). 
Amongst the rest of hypercoagulation markers that were evaluated in that study, plasmin-
antiplasmin complexes (PAP) also showed good results in terms of percentage of patients 
that returned to normal levels upon treatment (94% of them) (19). However, PAP was found 
altered in only 32% of the studied T. cruzi-infected participants before treatment and it was 




2.2. Biochemical markers of disease progression. 
 Besides the identification and validation of biomarkers for the early evaluation of 
treatment response, the other main area of research encompasses a whole series of studies to 
find biomarkers of pathogenesis progression. Their availability would promote the 
development of diagnostic tools based on them that could allow clinicians to adequately 
triage those chronically infected patients that will likely develop cardiac and/or digestive 
tissue disruptions from those that will not. Having such tests would permit to administer the 
limited resources to follow-up and manage Chagas disease patients in a most efficient 
manner. 
Cardiac damage is the most common clinical outcome observed in the symptomatic 
state of the disease (2,3). Thereby, markers of cardiac damage progression have been the 
most studied for Chagas disease (Figure 1). It is estimated that between 20% - 30% of T. 
cruzi chronically infected people will develop cardiomyopathy, and an early indicator of 
disease prognosis would help to prioritize treatment to those patients with a high risk of 
developing complications. Multiple biomarkers have been associated with Chagas disease 
cardiomyopathy (Table 1). However, although it has been proved that their levels increase 
accordingly to the severity of the damage, most of them are not able to distinguish between 
Chagas disease cardiomyopathy and other cardiomyopathies (20). 
Natriuretic peptides (brain and atrial) were among the first markers of cardiac disease 
progression ever considered. These are released under conditions of myocardial stress and 
have been shown to be increased in T. cruzi experimentally infected animals (21), and in 
Chagas disease patients with cardiomyopathy (22). Furthermore, levels of natriuretic 
peptides correlated to clinical prognosis (23). The N-terminal portion of brain natriuretic 
peptide (NT-proBNP) could be a better predictor than BNP itself, due to its high stability 
(24). Both peptides are strong predictors of mortality, and are some of the most well 
characterized markers for assessing early cardiac damage and predicting heart failure 
outcome. Measurement of BNP levels has also been suggested for the prognosis of patients 
presenting left ventricular systolic dysfunction, one of the typical signs of cardiac Chagas 
disease (22,25-27). 
The use of natriuretic peptides in the context of Chagas disease has also been studied 
in combination with other host-derived molecules. For example with cardiac troponin T 
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(cTnT), which is a marker of ischemia and inflammation (see next section for further details). 
A study assessing it in combination with NT-proBNP that included samples from 137 T. 
cruzi-infected patients with several forms of the disease found that levels of both markers 
were increased in those individuals with cardiomyopathy in comparison to the asymptomatic 
ones (28). Moreover, their values were increased accordingly to the severity of the 
cardiomyopathy (28). Plasma leptin levels and their relation to different forms of the disease 
were also studied in combination with NT-proBNP in 52 T. cruzi-infected patients, and those 
patients with heart failure had higher levels of NT-ProBNP and lower levels of leptin than 
controls (29). 
Angiotensin-converting enzyme 2 (ACE2) is another potential prognostic biomarker 
that has been evaluated. Wang and colleagues showed that ACE2 activity was significantly 
increased in those patients with signs of heart failure, but it was not so in patients without 
systolic dysfunction (30). Moreover, plasma ACE2 levels significantly correlated with 
clinical severity and echocardiographic (ECHO) parameters indicative of this (30). Similarly 
to cTnT and leptin, ACE2 activity was also compared to BNP levels in order to predict 
cardiac death and need of heart transplant, finding an additive predictive value when both 
markers were used in combination (30). Other enzymes that have been suggested as possible 
markers for early cardiac damage are glutamic oxaloacetic transaminase (GOT), glutamic–
pyruvic transaminase (GPT), alkaline phosphatase (ALP), acid maltase (AM) and alpha-
hydroxybutyric dehydrogenase (alphaHBDH), and their levels were found to be significantly 
altered in chagasic patients (31). Very interestingly, authors of that reference suggested that 
the finding of those released enzymes in patients without clinical evidence could represent 
good biomarkers of early myocardial damage (31). 
On the other side, the measurement of selenium (Se) levels has also been valued as a 
disease progression marker for cardiac as well as also for digestive manifestations (Figure 1; 
Table 1). In a cohort of 170 T. cruzi-infected people, Rivera and co-workers found that Se 
levels were lower in patients presenting the cardiac form of the disease compared with 
healthy donors or asymptomatic individuals (32). Moreover, such decrease of normal levels 
of Se was significantly correlated with malfunction of the ventricular ejection fraction. Low 
Se levels were also found in 6 out of the 10 T. cruzi-infected patients with digestive mega-
syndromes (32). In fact the use of Se as dietary supplementary was suggested as a possible 
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therapeutic strategy to preserve heart function in patients presenting the indeterminate form 
of the disease (33). 
Finally, another biochemical biomarker that has been researched for Chagas disease 
is endothelin 1, but the available data about it is yet controversial. A study performed in 2001 
showed that plasmatic levels of endothelin 1 were elevated in patients presenting T. cruzi 
infection related cardiomyopathy (34). However, Garcia-Alvarez and colleagues were not 
able to replicate those results, and reported in another study that similar plasmatic levels of 
endothelin 1 were observed in T. cruzi seropositive patients and control individuals (35). 
Moreover, the group of infected subjects presenting the undetermined form of the disease 
had even lower levels of endothelin 1 than controls (35). 
 
2.2.1. Biochemical markers of inflammation. 
Although the molecular mechanisms of Chagas disease pathogenesis are yet largely 
unknown, the presence of an inflammatory environment is a common feature to both cardiac 
and/or digestive tissue disruptions. Such continuous inflammation would lead to the 
occurrence of organ mega-syndromes, severe indicators of symptomatic chronic T. cruzi-
infection. Thereby, the prognostic value of host biochemical markers with inflammatory 
mediator function has also been evaluated. For instance C-reactive protein (CRP), which is 
liberated during the acute phase of inflammation and its serum levels associate to vascular 
inflammation and development of cardiovascular events (36). Several studies have evaluated 
this protein as a marker for the progression of Chagas disease, showing an association 
between chronic inflammation, cardiac manifestations and CRP levels (37,38). 
Other interesting marker under research is the enzyme adenosine deaminase (ADA). 
ADA regulates adenosine levels and its activity increases as a consequence of hypoxia and 
inflammation associated with immunologic events (39). In the same study, which included 
serum samples from 28 healthy individuals and from 82 T. cruzi-infected people presenting 
asymptomatic and symptomatic (cardiac) forms of the disease, it was shown that CRP and 
ADA levels linearly increased in connection to disease severity, and further correlated with 
the observed ECHO and electrocardiographic (ECG) parameters indicative of this state (39). 
Galectin-1 (Gal-1), found in human heart tissue, is also involved in immunological 
and inflammatory processes. A study with serum samples from healthy donors and patients 
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in the acute and chronic phases of Chagas disease showed that anti-Gal-1 IgG auto-antibodies 
specifically correlated with cardiac damage severity caused by T. cruzi infection as they were 
shown to be absent in non-related cardiomyopathies (40). Moreover, levels of Gal-1 were 
upregulated in cardiac tissue from patients presenting chronic T. cruzi infection, compared 
to cardiac tissue from healthy individuals (40). 
In the presence of excessive oxidative and nitric oxide (NO) stress, a post-
translational modification of cysteine residues of host proteins can occur. This modification, 
called S-nitrosylation (SNO), can affect cellular homeostasis and contribute to disease 
development. Recently, Zago and co-workers have shown that SNO modifications found in 
peripheral blood mononuclear cells from 53 Chagas disease patients were differentially 
abundant according to disease state, having the potential to identify disease severity (41). 
Matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) have 
also been investigated in the context of T. cruzi infection, but their participation in the disease 
progression is yet subject to controversy. A cross-sectional study with plasma samples from 
144 patients at different stages of Chagas disease and 44 samples from healthy donors 
showed that patients had increased levels of MMP-2 and MMP-9 (42). This work also 
reported that patients presenting ECG abnormalities had a significant increase of both 
enzymes compared to patients presenting the indeterminate form (42). In contrast, another 
study with serum samples from 193 T. cruzi-infected individuals observed an increase of the 
MMP-2/MMP-9 ratio that was associated with severity of the cardiac form of the disease 
(20). The study authors claimed that this ratio could be useful for assessing the progression 
from early inflammation to late fibrosis (20). T cruzi-infected subjects presented 
progressively higher levels of MMP-2, tissue inhibitor of metalloproteinase 1 (TIMP-1, 
inhibitor of MMP-9) and tissue inhibitor of metalloproteinase 2 (TIMP-2, inhibitor of MMP-
2) that paralleled cardiac severity (20). In line with that, Clark and colleagues have shown 
that serum levels of MMP-2 and TIMP-1 increased progressively in 85 individuals presenting 
cardiac structural changes, either in early or late stages of the disease (43). In comparison, 
other studies performed using serum and whole blood samples suggest that MMPs are 
differentially involved in Chagas disease cardiomyopathy: while MMP-2 would be 
associated to regulatory cytokines, MMP-9 would be correlated with inflammatory ones 
(44,45). Thus, MMP-2 would present a cardiac-protective and regulatory function, favoring 
10 
 
the indeterminate form of the infection, and MMP-9 would promote an inflammatory 
atmosphere, favoring the development of the cardiac form (44,45). 
Similarly to what occurs with BNP and NT-proBNP, high levels of creatine kinase-
MB (CKMB) indicate extensive damage and worse prognosis in patients suffering heart 
failure. Thus, this compound is commonly used as a measure of heart failure severity, and  
has been suggested as a possible biomarker for Chagas disease (20,46). A first study by 
Okamoto and colleagues assessing serum levels of BNP, NTproBNP, CKMB, troponin I, 
MMP-2, MMP-9, TIMP-1, TIMP-2, transforming growth factor beta 1 (TGFB1), and 
transforming growth factor beta 2 (TGFB2), showed no differences in biomarkers levels 
when stratifying patients by cardiac stage and T. cruzi infection status (20). This was the first 
time that CKMB was examined as a prognostic marker in Chagas cardiomyopathy. In that 
study, Okamoto and co-workers saw that troponin I levels (among others) rose in relation 
with an increasing severity of the disease stage, but unfortunately it did not distinguish 
between Chagas cardiomyopathy and other cardiomyopathies (20). However, Sherbuk and 
colleagues showed that CKMB, together with BNP, NTproBNP and MMP2, were 
significantly associated with mortality among patients presenting severe Chagas 
cardiomyopathy (46). Similarly, the conclusions from the cross-sectional case control 
retrospective study by Keating and co-workers, which measured CKMB, troponin, 
myoglobin, VCAM, NTproBNP as well as the cytokines IFN-γ, IL-6, IL-10 and TNF-α (see 
next section for more information about studies involving cytokines) pointed out that a clear 
pattern of inflammatory biomarkers was solely observed in those subjects presenting with 
the more severe cardiac symptomatic stages (36).  
As it was mentioned above, measuring serum levels of cTnT was analyzed as 
prognosis test of cardiac damage progression. Determining cTnT levels with a highly 
sensitive assay in serum samples from 26 healthy subjects and 179 chronically infected 
subjects concluded that those were significantly higher in patients suffering cardiomyopathy 
compared to the rest of groups (47). Moreover, authors of that work indicated that cTnT value 
correlated with the severity of that cardiomyopathy (47). Notably, CRP and IL-6 levels 
followed the same trend as cTnT changes (47).  
Finally, NO levels have been also reported to be significantly higher in patients with 
cardiomyopathy compared with asymptomatic patients and healthy donors (48–51). This 
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increase of NO levels in serum correlated with an increase of TNF-α, and a reduction in 
glutathione peroxidase (GPx) and superoxide dismutase (48). Alterations in the 
oxidant/antioxidant balance had been previously reported in a cohort of 80 T. cruzi infected 
patients, 50 healthy individuals, and 20 non-chagasic cardiomyopathy subjects (49). That 
study showed that T. cruzi-infected patients presented higher levels of malonylaldehyde and 
lower levels of glutathione, glutathione peroxidase, superoxide dismutase and manganese 
superoxide dismutase than healthy individuals. Patients presenting cardiomyopathy but 
negative for T. cruzi infection presented insignificant higher plasma malonylaldehyde levels 
compared to healthy patients, and their plasma antioxidant defense capacity was not 
compromised (49). Years later, the same group of researchers studied the role of 
inflammatory mediators such as myeloperoxidase, inducible nitric oxide synthase (iNOS) 
and xanthine oxidase, in the stimulation and sustenance of oxidative and nitrosative stress 
response in plasma samples of T. cruzi seropositive and seronegative patients (50). Those 
infected presented a significant increase in myeloperoxidase activity and protein level, 
advanced oxidation protein products, and 3-nitrotyrosine levels compared to healthy donors. 
However, plasma levels of xanthine oxidase and nitrate/nitrite contents were not altered. A 
correlation between increased myeloperoxidase activity and protein 3-nitrotyrosine 
formation was found, suggesting that myeloperoxidase could contribute to protein nitration 
and thus to oxidative and nitrosative damage in Chagas disease patients (50). More recently, 
the role of other markers of inflammation and oxidant/antioxidant status was studied in a 
cohort of 116 T. cruzi seropositive patients characterized as clinically-symptomatic or 
asymptomatic, 45 seronegative healthy individuals, and 102 T. cruzi seronegative patients 
presenting cardiac problems. Consistent with previous findings, seropositive subjects showed 
an increase in sera or plasma levels of myeloperoxidase, advanced oxidation protein 
products, nitrite, lipid peroxides and malonylaldehyde, and a decrease in superoxide 
dismutase and glutathione compared to healthy controls. Interestingly, myeloperoxidase and 
lipid peroxides levels correlated with clinical disease state, being potential biomarkers 
candidates for evaluating Chagas disease clinical severity (51). 
 
2.3. Markers associated with the host immune state. 
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The study of cytokines has also been suggested as a relevant tool for assessing cardiac 
disease progression (36). These and other biomarkers associated with the host immune state 
identified so far for Chagas disease are summarized in Table 2. In 2014, a study by Sousa et 
al. involving plasma samples of 176 T. cruzi infected people and 24 healthy individuals 
showed that the expression of plasma inflammatory cytokines, such as IFN-γ, TNF-α, IL-6, 
and IL-1β, was higher in those with cardiac form of the disease (52). These results were 
consistent with previous findings where high levels of TNF-α were found in patients 
suffering Chagas disease cardiomyopathy (48,53). Poveda and colleagues also found a higher 
expression of IFN-γ in serum samples from Chagas disease patients with cardiomyopathy 
compared to those with the indeterminate form (54). By contrast, indeterminate T. cruzi 
infected patients had a higher expression of IL-10 when compared with that of individuals 
with cardiac damage (54). Interestingly, IL-10 expression was associated with better cardiac 
function as determined by left ventricular ejection fraction and left ventricular diastolic 
diameter values (54). These results confirmed previous findings from Costa and co-workers, 
which suggested a cardiac-protective role for IL-10 in T. cruzi infection (55).  
In line with the former, other work has shown that high levels of IL-17 could correlate 
with better cardiac function, although this is considered a pro-inflammatory cytokine (56). 
Nonetheless, the role of IL-17 is still open to discussion because a recent study assessing 
plasma samples from 57 children showed that IL-17A levels were significantly higher in T. 
cruzi infected in comparison to seronegative individuals. Interestingly, those higher IL17A 
levels decreased to normal one year after treatment (57). 
Table 1. List of biochemical markers described up to date. Markers are ordered as they 
appear in the text. (Table 1 continues in next page). 
Biomarker name 
(acronym) 
Application evaluated (higher 
levels correlate to) 
References 
ApoA1, FBN Therapeutic response# (13,14) 
F1+2 and ETP Therapeutic response# (19) 
BNP Cardiac damage progression (20,22,23,25–27,30,43) 
                                                          
# Therapeutic response is associated with a decrease in the markers levels. 
* These markers with inflammatory mediators function are described separately in their own section 




NTproBNP Cardiac damage progression (20,24,28)  
cTnT* Cardiac damage progression (28,47)  
Leptin Cardiac damage progression (29) 
ACE2 Cardiac damage progression (30) 
GOT, GPT, ALP, AM, 
alpha-HBDH 
Cardiac damage progression (31) 
Selenium (Se) Cardiac and digestive disease 
progression 
(32) 
Endothelin Cardiac damage progression 
(controversial) 
(34,35) 
CRP* Cardiac damage progression (37–39) 
ADA* Cardiac damage progression (37) 
Gal-1, anti-Gal-1 auto-
antibodies 
Cardiac damage progression (40) 
NO* and SNO* Cardiac damage progression;  (41,48) 
MMP-2*, MMP-9* Cardiac damage progression 
(controversial) 
(20,42–46)  
TIMP-1*, TIMP-2* Cardiac damage progression (20,46) 
CKMB, troponin I, 
TGFβ1, and TGFβ2 
Cardiac damage progression (20,36,43,47) 
Biomarker name 
(acronym) 
Application evaluated (higher 









superoxide dismutase  




oxide synthase, xanthine 
oxidase, oxidation protein 
products, 3-nitrotyrosine, 
nitrate/nitrite  
Cardiac damage progression (50,51) 
Lipid peroxides Cardiac damage progression (51) 
 
At present, despite the identification of cytokine signatures indicative of a pattern of 
pathogenesis progression has been pursued, the only tests that would independently have 
value for clinical decision would be the aforementioned NTproBNP (see section 2.2) and the 
detection of T. cruzi DNA by PCR, as far as they are accompanied with electrocardiographic 
(ECG) and ECHO clinical assessments (36). 
Other studies have focused on the potential role of adaptive immune response 
mediators as biomarkers. In relation to humoral immunity, the possible impact of anti-
troponin T and myosin autoantibodies has been suggested (58). Serum samples from 131 
patients presenting different clinical forms of Chagas disease, healthy donors, and patients 
with ischemic cardiomyopathy were included in a study whose results showed that specific 
anti-T. cruzi antibodies and autoantibodies against myosin and troponin T are frequently co-
detected in high levels in patients with chronic Chagas disease (58). Even though anti-
troponin T autoantibodies levels were very similar in patients presenting the indeterminate 
form of the disease and in patients presenting cardiac symptoms, the study found a correlation 
between cardiac Chagas disease, the production of anti-troponin T and anti-myosin 
autoantibodies, and a diminished left ventricular ejection fraction, which is an important 
indicative of systolic dysfunction (58). Anti-T. cruzi specific antibodies and their correlation 
with disease progression and cardiac damage have also been evaluated. In a cohort of 55 T. 
cruzi infected patients (20 presenting the indeterminate form of the disease and 35 suffering 
cardiac damage) an inverse correlation between anti-T. cruzi IgG1 titers and left ventricular 
ejection fraction was found in patients presenting the cardiac form of the disease, indicating 
a worse prognosis for those T. cruzi-infected patients presenting high titers of anti-T. cruzi 
IgG1 (59). Thus, anti-T. cruzi IgG1 levels could be an interesting biomarker to predict the 
severity of chronic Chagas disease cardiomyopathy. 
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In terms of T cell immune responses, it has been recently described that Chagas 
patients with cardiac tissue damage present higher expression levels of T-cell inhibitory 
receptors and lower antigen-specific capacity compared with that of asymptomatic patients 
(60). These features were partially reversed by BNZ treatment in both asymptomatic and 
symptomatic patients: the co-expression of inhibitory molecules was reduced, the 
multifunctional antigen-specific response of CD8+ T cells was enhanced, and an increase in 
the subset of cells with cytotoxic proprieties and production of IFN-γ was observed. These 
results point at a potential application of the analysis of those immunological signatures as 
biomarkers of disease progression and treatment response. 
  
3. Other types of host-derived Chagas disease biomarkers.  
3.1. Extracellular vesicles. 
Extracellular vesicles (EVs) are cell-derived membranous nanoparticles released by 
most cells, present in all body fluids, and implicated, as intercellular communicators, in 
diverse pathological processes (61). Mainly for these reasons, EVs hold an enormous 
potential as predictive biomarkers for human diseases, including several parasitic diseases 
(62,63). 
In Chagas disease, the possible role of EVs as active communicators between T. cruzi 
and its host, as well as the implications of this interaction in parasite tropism and changes in 
immune status during the chronic phase of the disease, has been recently reviewed (64). 
Moreover, the use of EVs as potential diagnostic biomarkers during the  
Table 2. List of immune-related molecules studied as markers for the evaluation of cardiac 
damage progression. 
 
Name of the marker or combinations 
of markers 




TNF-α Progression (48,52,53) 
Chemokine C-C ligands 2 and 3 
(CCL2, CCL3) 
Progression (53) 
IL-6 Progression (37,47) 
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IL-10 Protection (55) 
Anti-troponin T antibodies, myosin 
autoantibodies 
 Progression (58) 
IFN-γ, IL-1β Progression (52) 
IL-2, IL-4, IL-5, IL-9, IL-12p70, IL-13, 
IL-22 
Progression/Protection (54) 
IL17, IL-17A Controversial (55-57) 










course of the disease has been recently reported in several studies. Diaz Lozano and 
collaborators showed that EVs secreted by the infective forms of T. cruzi are targeted by the 
immune system forming immune complexes that could be used as biomarkers of prognosis 
for digestive Chagas disease (65). In addition, EVs released by human THP-1 cells after 
interacting with different stages of T. cruzi parasites are differently recognized by antibodies 
present in sera from infected individuals with the indeterminate or the cardiac form of the 
disease (66). Moreover, it has also been shown that circulating micro-particles secreted by 
Chagas disease patients induce pro-inflammatory activation and nitrosative response in THP-
1 macrophage cells, which is dependent of the clinical stage of the patients (67). 
Proteomic analysis to determine the molecular composition of EVs secreted by 
different T. cruzi parasite stages have been reported in recent years (68–70). However, to the 
best of our knowledge the protein-cargo associated to EVs circulating in peripheral blood of 
T. cruzi-infected subjects has not been evaluated in the context of therapeutic response. In 
this regards, unpublished results by Cortes-Serra et al. describe for the first time, human and 
T. cruzi proteins present or upregulated in plasma-derived EVs from a chronic Chagas disease 
patient before chemotherapy and that are absent or downregulated following treatment. 
Although these results derive from the analysis of a single heart-transplanted patient 
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presenting severe cardiac complications, they represent a proof-of-principle of the potential 
of this approach to discover new biomarkers of therapeutic response. 
 
3.2. Markers derived from human genetic studies.   
 Chagas disease has a multifactorial etiology that involves complex host-parasite 
interactions governed by parasite and host genetics, which can be as well influenced by 
environmental factors. As it was mentioned before, the mechanisms of pathogenesis of 
chronic T. cruzi infection are yet largely unknown. But immune system mediators have been 
described to participate in driving heart and/or gut tissues inflammation, either through 
response to the parasite presence and, to a certain level, by autoimmune reactions (71). Thus, 
most of the genetic studies performed so far have searched for sequence variations that could 
be associated to chronic Chagas cardiomyopathy susceptibility in immune system related 
genes. These searches followed a hypothesis-driven approach to find single nucleotide 
polymorphisms (SNPs) in genes known or suspected to play a role in those inflammatory 
phenomena (72). Amongst the genes studied there are: human leukocyte antigen (HLA) class 
I and class II alleles, cytokines (e.g.: IL-1β, IL-10, TNF-α, IL-17, IL-18) and chemokines 
and their receptors (MCP1/CCL2, CCR5, MIG/CXCL9, IP10/CXCL10) (reviewed in (72)), 
as well as inflammasome genes (73). Some variations were associated to chronic Chagas 
cardiomyopathy, but in other traits like TNF-α controversy is open mainly due to the limited 
sample size analyzed and the ample genetic heterogeneity of the studied cohorts. These 
features have also limited the only genome-wide association study (GWAS) performed so 
far in Chagas disease (74). With the power of its “hypothesis-free” and “hypothesis-
generating” nature, unfortunately this study did not report any significant associations with 
chronic cardiomyopathy at the genomic level. However it interestingly suggested that SNPs 
in the solute carrier family gene SLCO1B1 associated to a cardiomyopathy phenotype (74). 
Other kind of genetic studies, such as transcriptomics and epigenetics works, will be 
also required in order to functionally expand and integrate the aforementioned genomics data, 
as well as to comprehend the impact of environmental factors in the susceptibility to the 
disease. In this regard, a whole-blood transcriptome of T. cruzi-infected subjects and 
uninfected controls identified a signature of 27 genes, mainly related to natural killer (NK) 
and CD8+ T cells, which would mark a disease progression pattern (75). Whereas Frade et 
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al. analyzed the whole-transcriptome of heart biopsies from chronic Chagas cardiomyopathy 
patients and identified a long non-coding ribonucleic acid (RNA) molecule that had been 
associated to heart failure (76). Long non-coding RNAs are >200 nt long RNA transcripts 
that have been described to have a broad functionality in the regulation of gene expression at 
transcriptional, post-transcriptional and epigenetics levels (76). 
Other series of studies analyzed the differential expression of micro RNAs (miRNAs) 
in chronic cardiomyopathy Chagas patients, either versus those suffering from idiopathic 
dilated cardiomyopathy (77), or comparing them to T. cruzi-infected subjects at the 
indeterminate stage and a group of non-infected subjects (78,79). These miRNAs are small 
non-coding RNA molecules with a cell and tissue specific expression pattern that are 
involved in post-transcriptional regulation and might target up to 60% of the human genes 
(80). A work integrating miRNA and gene expression profiles of T. cruzi acutely infected 
mice heart tissues suggested a correlation between those miRNAs and the observed 
pathobiology (81). Such miRNAs can be epigenetic regulators and be regulated 
epigenetically at the same time (82). One of the most common epigenetic modifications is 
deoxyribonucleic acid (DNA) methylation, and the results from a whole-genome cardiac 
fingerprinting study revealed that up to 399 genes were differentially methylated and 
expressed in chronic Chagas cardiomyopathy patients in comparison to healthy controls (83). 
The above mentioned studies are very necessary to achieve a deeper understanding 
of Chagas disease complex pathogenesis events. However, so-called genomic medicine yet 
lies far from being applicable for Chagas disease. The usefulness of those genetic markers in 
the field as potential markers of disease prognosis will largely depend on a much awaited 
generalization of molecular-based diagnostics, or the development of easier-to-use molecular 
based detection methods such as loop-mediated isothermal amplification (LAMP) or 
recombinase polymerase amplification (RPA) assays based on them.   
 
4. Conclusions. 
 We are still far from having a licensed test for the early assessment of treatment 
efficacy or to accurately anticipate Chagas disease progression. Many candidate molecules, 
parasite- and host-derived, have been evaluated so far. Most of the studies have generally 
been limited to the evaluation of a few dozen of samples. Larger study cohorts, which should 
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ideally involve individuals from varied geographic origins and accurate clinical stratification 
according to the distinct disease stages, should be pursued in order to obtain robust results as 
well as to shed light onto those markers that still have controversial results. In addition, the 
length of the follow up periods should be extended to up to 5 years post-treatment particularly 
for studies on therapeutic response biomarkers. In relation to studies on biomarkers to 
evaluate pathogenesis progression, an even longer longitudinal follow-up of participants 
would be desirable. This is because in the majority of studies performed so far cardiac 
alterations (assessed by ECG and ECHO) are already present at the time of triaging the study 
groups. With current designs it would not be possible to assign a clinical decision on the 
patients´ management upon observed changes in the markers´ levels, as these were found in 
patients already symptomatic. Thus, those markers that appear altered at indeterminate stages 
with no evidences of clinical signs should be therefore the most promising. 
Regardless of their application, assessment of the markers with the same cohort of 
samples could also contribute to draw a clearer picture. In this sense, multinational scientific 
networks  like NHEPACHA (10) are very interesting initiatives so as to bring together 
academic, clinical and industry groups, providing them with the environment to 
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